Sunovion Pharmaceuticals Inc.
84 Waterford Drive
About Sunovion Pharmaceuticals Inc.
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people living with serious medical conditions. Our vision is to lead the way to a healthier world, and we believe scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything we do, we have charted new paths to life-transforming treatments reflecting ongoing investments in R&D and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.
302 articles with Sunovion Pharmaceuticals Inc.
Sunovion Announces Positive Clinical Study Results For Latuda (Lurasidone HCL) In Adolescents With Schizophrenia
The American College of Chest Physicians And Sunovion Announce Strategic Initiative Focused On The Importance Of Drug Delivery In The Management Of COPD
Sunovion Announces FDA Filing Acceptance Of New Drug Application For SUN-101/Eflow For The Treatment Of Patients With Chronic Obstructive Pulmonary Disease (COPD)
Sunovion Announces Results From Pivotal Study Evaluating Novel Drug Candidate Dasotraline In Children With ADHD
Massachusetts' Sunovion Swallows Up Cynapsus in $624 Million Deal, Gains Experimental Parkinson's Drug
Sunovion Pharmaceuticals Inc. Hands On! Annual Community Service Program Contributes More Than 20,000 Employee Volunteer Hours Over Five Years To Support Youth Organizations And Community Relief Efforts
Sunovion Pharmaceuticals Inc. Announces Publication Of Data Evaluating Dose Escalation Of Latuda (Lurasidone HCL) In The Treatment Of Schizophrenia
Sunovion Pharmaceuticals Inc. Submits New Drug Application For SUN-101/Eflow To The FDA For The Treatment Of Patients With Chronic Obstructive Pulmonary Disease (COPD)
Sunovion Pharmaceuticals Inc. Announces Results Of Phase III Long-Term Safety Study Showing SUN-101/Eflow® (Glycopyrrolate) Was Well-Tolerated In People With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD)
PARI Pharma's Investigational Closed eFlow Nebulizer System Used In Two Successful Phase 3 Clinical Studies Evaluating Sunovion Pharmaceuticals Inc.'s SUN-101 (Glycopyrrolate) In People With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (C
Sunovion Pharmaceuticals Inc.Announces Publication Of Data Evaluating The Long-Term Safety And Tolerability Of Latuda (Lurasidone Hcl) In The Treatment Of Bipolar Depression
Sunovion Pharmaceuticals Inc. Announces Health Outcomes Data On Exacerbation-Related Hospitalizations That Support The Use Of Brovana (Arformoterol Tartrate) Inhalation Solution In People With Moderate-To-Severe COPD At The 2016 American Thoracic Society
American Thoracic Society And Sunovion Pharmaceuticals Inc. Release Landmark Survey Of Pulmonologists’ Attitudes And Practices With Inhalation Devices For COPD At The ATS 2016 International Conference
Sunovion Pharmaceuticals Inc. To Present Data On Latuda (Lurasidone Hcl) At The 169th Annual Meeting Of The American Psychiatric Association
Sunovion Pharmaceuticals Inc. Presents New Health Outcomes Data Supporting Brovana (Arformoterol Tartrate) Inhalation Solution In People With Moderate-To-Severe COPD At The 2016 American Thoracic Society International Conference
Sunovion Pharmaceuticals Inc. Announces Positive Results From Two Phase III Clinical Studies Evaluating SUN-101/Eflow (Glycopyrrolate) In People With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Sunovion Pharmaceuticals Inc. Announces Results Of Health Outcomes Analyses Supporting The Use Of Aptiom (Eslicarbazepine Acetate) In People With Partial-Onset Seizures At The 68th American Academy of Neurology Annual Meeting
Sunovion Pharmaceuticals Inc. To Present Data Analyses Supporting Use Of Aptiom (eslicarbazepine acetate) At The 68th American American Academy of Neurology Annual Meeting
PsychoGenics Inc. Drug Discovery Collaboration With Sunovion Pharmaceuticals Inc. Achieves A Milestone